Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema

/ Publications / Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema

Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema

Authors: Toto, L; D’Aloisio R, Quarta A et al.
Presented: January 1, 2022
Type: Publications

The combined treatment showed good anatomical and functional outcomes for the treatment of DMO. In addition, IDI/SML seems to reduce injection frequency over time, improving patients’ quality of life and reducing the socio-economic burden.

Related publications and webinars

From Minimally Invasive Procedure to Photocoagulation: Personalized retinal care with Navilas® (Japanese)

  • Type:
  • Presented:February 8, 2024
Priv.-Doz. Dr. med. Yoko Miura

On-Demand Webinar: Navilas in der täglichen Praxis

  • Type:
  • Presented:February 1, 2017
Dr. Bernd Fassebender
  • The treatment strategy and selected parameters presented in content listed here are solely the responsibility of the treating ophthalmologist, who is required to be familiar with the most recent literature/guidelines or recommendations, as well as with the usage of the Navilas Laser System according to the current Operator’s Manual.